Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Aggressive anticoagulation  (1)
  • Biochemical bone markers  (1)
  • CK Isoenzymes  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Monitoring prothrombin fragment 1+2 during initiation of oral anticoagulant therapy after intracoronary stenting (1992)
    Springer
    Annals of hematology 65 (1992), S. 83-87 
    Details
    ISSN: 1432-0584
    Keywords: Intracoronary stenting ; Aggressive anticoagulation ; Subacute occlusion ; Bleeding complication ; Prothrombin fragment 1+2
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Patients with intracoronary stent implantation are treated with aggressive anticoagulant and antiplatelet therapy consisting of high-dose heparin, phenprocoumon, acetylsalicylic acid, dipyridamole, and the infusion of dextran to prevent a subacute thrombotic occlusion of the stented segment. In an effort to optimize this treatment by reducing both imminent bleeding complications and subacute thrombotic occlusion, the concentrations of prothrombin fragment 1+2 (F1+2) were determined after intracoronary Palmaz-Schatz stent implantation in 19 consecutive patients. The F1+2 concentrations after stent implantation and before the initiation of oral anticoagulant therapy (OAT) were 0.35 nm/l and 0.25–0.53 nm/l (median and 25th–75th percentile), versus 0.74 nm/l and 0.52–0.78 nm/l, in healthy subjects and 0.61 nm/l and 0.30–1.02 nm/l in 15 patients with ongoing proximal DVT. Nine days after initiation of OAT, F1+2 concentrations in both patient groups had not yet reached levels observed in patients with OAT in the stable state (0.16 nm/l, 0.12–0.26 nm/l;n=76;P〈0.0001 compared with healthy subjects; INR 2.0–4.5). Despite an INR greater than 2.0, accompanying heparinization was terminated on day 9. In two stented patients a minor bleeding complication arose after the removal of the arterial catheter. Subacute thrombotic occlusions were not observed. Since F1+2 concentrations did not exceed the upper limit of normal range (1.11 nm/l) in any of the 19 patients, the therapeutic regimen was not changed. Monitoring F1+2 may thus be helpful in introducing a more individual treatment if aggressive anticoagulation has to be performed.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01698135
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Biochemical bone markers compared with bone density measurement by dual energy X-ray absorptiometry (1995)
    Springer
    Calcified tissue international 57 (1995), S. 253-257 
    Details
    ISSN: 1432-0827
    Keywords: Bone density measurement ; Dual energy X-ray absorptiometry ; Collagen type I ; Biochemical bone markers ; b-quotient
    Source: Springer Online Journal Archives 1860-2000
    Topics: Biology , Medicine , Physics
    Notes: Abstract In contrast to medical imaging, the biochemical markers allow a more frequent determination and are not as invasive as histomorphometric methods. We investigated biochemical markers of type I collagen compared with bone density measurements in 85 females between 41 and 89 years of age (median: 57 years). The bone density measurements were performed by dual-energy X-ray absorptiometry (DXA) on the lumbar spine (L1–4). The bone density measurements were stated as percentage of the norm. All patients were divided into three groups: I=〈80%; II=80–120%; III=〉120%. Based on this classification the median concentration of the I-carboxyterminal propeptide of type I procollagen in serum (S-PICP) as an anabolic marker of type I collagen increased significantly with rising bone density: I 65.0* μg/liter (interquartile range: 52.1–78.0 μg/liter); II 85.9* μg/liter (52.1–115.5 μg/liter); III 81.4 μg/liter (62.0–101.0 μg/liter); * P〈0.05. The concentration of urinary pyridinolines (U-PYR) as a marker for degradation of type I collagen decreased. The I-carboxyterminal telopeptide (S-ICTP) and osteocalcin (S-BGP) did not change. The multivariate regression analysis showed no relationship between bone density measurement and biochemical bone markers. Only the age significantly correlated negatively with bone density measurement. For a better assessment of type I collagen metabolism we created a “b-quotient” by dividing the sum of S-PICP and S-BGP by U-PYR. The median b-quotient increased significantly: I 1.55*+ (0.97–2.04); II 2.09* (1.57–2.86); III 2.46+ (1.58–3.22);*+ P〈0.05. Changes in bone metabolism cannot be identified by the determination of a single marker. However, the improved biochemical diagnostic measurement using the b-quotient may provide early information about the progression of a metabolic disorder within the interval of imaging.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00298879
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Creatinkinase — Isoenzyme: Idiopathisches Auftreten von Creatinkinase-BB-Aktivitäten im Serum von Patienten (1978)
    Springer
    Journal of molecular medicine 56 (1978), S. 641-646 
    Details
    ISSN: 1432-1440
    Keywords: CK Isoenzymes ; Immunological inhibition method ; Epidemiology ; CK-Isoenzyme ; Immunologische Inhibitionsmethode ; Epidemiologie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Bei der Differenzierung der Aktivitäten von Creatinkinase-Isoenzymen im Serum von Patienten mit immunologischen Methoden kann das in der Literatur beschriebene Vorkommen von Creatinkinase-BB-Aktivitäten bei verschiedenen Krankheiten bzw. Operationen im allgemeinen nicht bestätigt werden. Jedoch wird bei Patienten höheren Lebensalters (57–85 Jahre mit einer Ausnahme) mit einer Frequenz von größenordnungsmäßigl:1000 Creatinkinase-BB-Aktivität gefunden. Die Aktivitäten betragen 15–234 U/l bzw. 19–94% der Gesamt-Creatinkinase-Aktivitäten. Bisher kann kein Zusammenhang mit einer bestimmten Krankheit hergestellt werden. Diese Fälle werden dadurch erkannt, daß die Bestimmung von CK-MB-Aktivitäten mit dem Immun-Inhibitionstest abnorm hohe Werte ergibt (60–202% der Gesamt-Creatinkinase-Aktivität), die zu einer Nachprüfung mit dem Immun-Präcipitationstest führen. Die bisher untersuchten Fälle werden vorgestellt und diskutiert.
    Notes: Summary By differentiation of creatine kinase isoenzyme activities in sera using immunological methods the published data about occurrence of creatine kinase BB activities in patients with different diseases or after surgical treatment, respectively, cannot be verified in general. With a frequency in the order of magnitude of 1:1000 in the serum of old patients (age 57 to 85 years with one exception), however, creatine kinase BB activities can be measured. The range of activities is 15 to 234 U/l, or 19 to 94% of total creatine kinase activities, respectively. At the present time there is no possibility to correlate this phenomenon to any specific disease. These cases are detected by abnormally high results of CK-MB activity measurements with the immunoinhibition test (range 60 to 202% of total creatine kinase activities) which lead to a repeated analysis using immunoprecipitation. The results of all CK-BB patients investigated till now are presented and discussed.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01477017
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...